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A record-linkage study was carried out between the Italian AIDS Registry and 24 Italian cancer registries to compare cancer excess
among persons with HIV/AIDS (PWHA) before and after the introduction of highly active antiretroviral therapy (HAART) in 1996.
Standardised incidence ratios (SIR) were computed in 21951 AIDS cases aged 16–69 years reported between 1986 and 2005. Of
101669 person-years available, 45026 were after 1996. SIR for Kaposi sarcoma (KS) and non-Hodgkin lymphoma greatly decreased
in 1997–2004 compared with 1986–1996, but high SIRs for KS persisted in the increasingly large fraction of PWHA who had an
interval of o1 year between first HIV-positive test and AIDS diagnosis. A significant excess of liver cancer (SIR¼6.4) emerged in
1997–2004, whereas the SIRs for cancer of the cervix (41.5), anus (44.0), lung (4.1), brain (3.2), skin (non-melanoma, 1.8), Hodgkin
lymphoma (20.7), myeloma (3.9), and non-AIDS-defining cancers (2.2) were similarly elevated in the two periods. The excess of
some potentially preventable cancers in PWHA suggests that HAART use must be accompanied by cancer-prevention strategies,
notably antismoking and cervical cancer screening programmes. Improvements in the timely identification of HIV-positive individuals
are also a priority in Italy to avoid the adverse consequences of delayed HAART use.
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Three types of cancer that occur in HIV-positive individuals,
namely Kaposi sarcoma (KS), non-Hodgkin lymphoma (NHL),
and invasive cervical cancer (ICC), are currently included in the
European clinical AIDS definition (Ancelle-Park, 1993). How-
ever, excesses of some non-AIDS defining cancers have been
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particular Hodgkin lymphoma (HL), and cancers of the anus, lung,
and liver (Grulich et al, 2007).
After the introduction of the highly active antiretroviral therapy
(HAART) in 1996, huge declines in KS and NHL incidence have
been consistently reported in high-resource countries (Grulich
et al, 2002; Franceschi et al, 2003, 2008; Engels et al, 2008; Polesel
et al, 2008). The ultimate influence of the partial immune
reconstitution and improved survival made possible by HAART
on the risk of ICC and non-AIDS-defining cancers, notably HL,
anal and liver cancer is, however, still unclear (Herida et al, 2003;
Clifford et al, 2005; Dal Maso et al, 2005; Biggar et al, 2006; Engels
et al, 2006; Hessol et al, 2007; Patel et al, 2008).
In Italy, a high-quality centralised AIDS Registry is active on a
nationwide scale (Centro Operativo AIDS, 2008), whereas cancer
registries (CRs) cover nearly one-third of the population (Curado
et al, 2007). The aim of the present study was to provide updated
information on cancer excess in Italian PWHA after the
introduction of HAART, and compare it with corresponding
findings prior to 1997. Attention will also be paid to the cancer
pattern among the growing proportion of late presenters; that is,
PWHA whose first HIV-positive test was concomitant with AIDS
diagnosis (450% of new AIDS cases since 2002 in Italy, Centro
Operativo AIDS, 2008).
MATERIALS AND METHODS
The general design of our record-linkage study has been described
previously (Franceschi et al, 1998; Dal Maso et al, 2003). In brief,
reporting of AIDS cases to the Italian AIDS Registry started in 1982
on a voluntary basis and became mandatory in November 1986. At
the end of 2005, a total of 57531 AIDS cases had been reported
nationwide (Centro Operativo AIDS, 2008). The AIDS Registry has
been recording information on CD4þ cell count, and HAART use
at AIDS diagnosis, since 1990 and 1999, respectively, and that on
first HIV-positive test since 1996.
A network of CRs has been active in Italy since the early 1980s
(AIRT Working Group, 2006). In the late 1990s, 24 CRs had been
established and included a population of 17.3 million (30% of the
total Italian population, Table 1, Curado et al, 2007). Cancer
registries vary both in size, covering populations of approximately
180000 to nearly 2.1 million, and in duration of activity (Table 1).
Routine indicators of data completeness and quality in Italian CRs
are, however, satisfactory (Curado et al, 2007).
Record linkage between the AIDS Registry and CRs was
performed using an updated version of an ‘ad hoc’ software
application designed previously and validated (Dal Maso et al,
2001). Briefly, records were linked by last and first name, and by
date of birth. The name–date algorithm required: (a) that the
records be identical for at least one critical field and (b) that the
other two critical fields, if not identical, differ only in prescribed
ways. The procedures removed all personal identifiers and, hence,
registry staff was blinded to which persons had been linked.
The present study was restricted to AIDS patients who: (1) were
diagnosed with AIDS between 1986 and 2005; (2) were aged
between 16 and 69 years at the time of AIDS diagnosis and (3)
reported a ‘legal residence’ in areas covered by a CR. Person-years
at risk were computed between 5 years prior to AIDS diagnosis,
and the date of cancer or death or 10 years after AIDS diagnosis,
Table 1 Cancer registry characteristics, AIDS diagnoses, and linked cancers from 24 Italian cancer registries
Reporting period Linked cancers
c
All cases
Cancer registry Pre-HAART Post-HAART
Population
( 1000)
a AIDS cases
b KS NHL ICC Other Pre-HAART Post-HAART
Alto Adige/Su ¨dtirol 1995–1996 1997–2002 460 230 7 4 0 4 7 8
Biella 1995–1996 1997–2002 189 268 4 8 1 3 6 10
Brescia — 1999–2001 1012 1909 13 17 2 12 0 44
Ferrara 1991–1996 1997–2002 314 959 19 21 1 9 25 25
Florence 1985–1996 1997–2003 1162 1199 133 86 2 44 186 79
Friuli Venezia Giulia 1995–1996 1997–2003 1188 407 13 10 1 5 8 21
Genoa 1986–1996 1997–2003 920 1775 91 85 10 46 155 77
Macerata 1991–1996 1997–2000 293 135 7 3 1 1 6 6
Milan — 1999–2002 1256 4822 28 40 3 34 0 105
Modena 1988–1996 1997–2004 615 633 45 36 2 11 48 46
Naples 1996 1997–2003 541 110 5 2 0 1 1 7
Parma 1978–1996 1997–2003 394 368 24 21 1 11 31 26
Ragusa 1981–1996 1997–2003 291 63 2 5 0 0 5 2
Reggio Emilia 1996 1997–2004 450 412 15 24 2 8 11 38
Romagna 1985–1996 1997–2004 803 1948 94 104 3 55 149 107
Salerno 1996 1997–2001 1088 223 4 4 1 2 0 11
Sassari 1992–1996 1997–2003 469 374 12 20 2 7 24 17
Sondrio — 1998–2002 177 118 1 1 0 1 0 3
Syracuse — 1999–2002 396 157 1 4 0 2 0 7
Trento 1995–1996 1997–2002 460 347 7 16 0 6 7 22
Turin 1985–1996 1997–2002 1091 1794 108 61 1 40 145 65
Umbria 1994–1996 1997–2003 831 435 18 28 1 9 30 26
Varese 1976–1996 1997–2002 800 1668 62 98 3 30 125 68
Veneto 1987–1996 1997–2002 2077 1599 88 74 2 42 129 77
Total 17277 21951 801 772 39 383 1098 897
HAART¼highly active antiretroviral therapy, KS¼Kaposi sarcoma, NHL¼non-Hodgkin lymphoma, ICC¼invasive cervical cancer.
aObserved population in 1997–2002.
bAIDS
cases notified in cancer registry areas in 1986–2005.
cCancers reported to cancer registries in people with AIDS, aged 16–69 years, between 1986 and 2004 from 5 years prior
to 10 years after AIDS diagnosis (at/after AIDS for AIDS-defining cancers).
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if no complete CR data were available for the corresponding years.
To reduce losses to follow-up, dates of death were updated through
record linkage with the National Mortality Database.
Observed cases included incident cancer cases reported to CRs
during the above-defined person-years at risk. Cancer site and type
were classified according to the International Classification of
Disease, 10th revision (World Health Organisation, 1992) and were
checked for quality by CR coordinators. The basis of diagnosis was
reported either as microscopic confirmation, including histologi-
cal, haematological, or cytological confirmation, or as other, that
is, clinical, instrumental diagnosis, or death-certificate-only. When
an AIDS-defining cancer was mentioned in both the AIDS Registry
and a CR, the earliest date of cancer diagnosis was retained. When
KS was reported in a CR before the date of AIDS diagnosis in the
AIDS Registry, AIDS onset was backdated. The same was done for
NHL and ICC when they had been reported to a CR within 5 and 2
years, respectively, before AIDS diagnosis.
Expected numbers of different cancers were computed for each
CR from sex-, age-, and period-specific incidence rates (Parkin
et al, 1992, 1997, 2002; Curado et al, 2007). Observed numbers of
cancer in PWHA were compared with expected numbers by means
of standardised incidence ratios (SIRs), and corresponding 95%
confidence intervals (CI) were computed using the Poisson
distribution (Breslow and Day, 1987).
SIR were calculated for calendar period, distinguishing the pre-
HAART (1986–1996) from the post-HAART (1997–2004) period. For
1997–2004, and for cancers showing a significantly increased risk and
at least 10 cases, SIRs were also computed separately by age group
(16–34, and 35–69 years), HIV transmission category (injecting drug
users (IDUs), men who have sex with men (MSM), heterosexuals) and
time of cancer occurrence in respect to AIDS diagnosis (4–60 months
before, from 3 months before to 3 months after, 4–60 months after,
and 61–120 months after). SIR were also computed separately by
interval between first HIV-positive test and AIDS diagnosis (o1, 1–9,
X10 years), and country of birth (Italy or other).
Table 2 Observed (Obs) and expected (Exp) cancers in persons with HIV/AIDS
a, standardised incidence ratio (SIR), and corresponding 95% confidence
interval (CI) by year of cancer diagnosis. Italy, 1986–2004
Year of cancer diagnosis
1986–1996 (56643py) 1997–2004 (45026py)
ICD10; Cancer type or site Obs Exp SIR (95% CI) Obs Exp SIR (95% CI)
AIDS-defining cancers
C46; Kaposi sarcoma 507 0.3 1792 (1640–1956) 294 0.5 572 (508–641)
C82–C88, C96; NHL 420 0.8 497 (450–546) 352 3.8 93.4 (83.9–104)
C53; Cervix uteri 9 0.2 51.0 (23.1–97.3) 30 0.7 41.5 (28.0–59.3)
Non-AIDS-defining cancers
C00–C14, C30–C32; Head and neck 6 4.4 1.4 (0.5–3.0) 11 6.0 1.8 (0.9–3.3)
C15; Oesophagus 0 0.6 — 2 0.8 2.5 (0.2–9.1)
C16; Stomach 6 3.2 1.9 (0.7–4.1) 6 3.9 1.6 (0.6–3.4)
C18; Colon 2 3.9 0.5 (0.0–1.9) 9 6.2 1.4 (0.7–2.7)
C19–C20; Rectum and rectosigmoid junction 5 2.0 2.5 (0.8–5.9) 7 3.1 2.3 (0.9–4.7)
C21; Anus 6 0.2 35.5 (12.8–77.7) 11 0.3 44.0 (21.8–78.9)
C22; Liver 3 1.4 2.1 (0.4–6.4) 16 2.5 6.4 (3.7–10.5)
C23–C24; Biliary tract 0 0.4 — 2 0.5 3.9 (0.4–14.5)
C25; Pancreas 2 1.2 1.7 (0.2–6.3) 2 1.8 1.1 (0.1–4.1)
C33–C34; Trachea and lung 17 8.2 2.1 (1.2–3.3) 42 10.3 4.1 (2.9–5.5)
C37–C38; Thymus, heart, mediastinum, pleura 1 0.3 3.9 (0.0–22.6) 1 0.3 3.3 (0.0–18.7)
C40–C41; Bone and articular cartilages 1 0.4 2.5 (0.0–14.0) 1 0.4 2.6 (0.0–14.6)
C43; Melanoma 3 3.4 0.9 (0.2–2.6) 3 5.3 0.6 (0.1–1.7)
C44; Skin non-melanoma 18 8.7 2.1 (1.2–3.3) 28 15.6 1.8 (1.2–2.6)
C45; Mesothelioma 0 0.3 — 1 0.4 2.2 (0.0–12.8)
C47, C49; Peripheral nerves, soft/connective tissues 0 0.8 — 3 0.9 3.2 (0.6–9.5)
C50; Breast
b 3 4.0 0.8 (0.1–2.2) 5 8.7 0.6 (0.2–1.4)
C54; Endometrium 0 0.4 — 1 0.7 1.5 (0.0–8.3)
C56; Ovary 1 0.6 1.7 (0.0–9.7) 0 0.8 —
C51, C52, C57; Vulva and vagina 2 0.1 24.6 (2.3–90.6) 3 0.1 24.3 (4.6–71.8)
C55; Utero, unspecified 1 0.0 25.2 (0.0–145) 0 0.0 —
C60, C63; Penis 0 0.1 — 3 0.2 12.0 (2.3–35.5)
C61; Prostate 2 1.5 1.3 (0.1–4.7) 0 5.3 —
C62; Testis 5 3.5 1.4 (0.5–3.4) 2 2.9 0.7 (0.1–2.5)
C64–C66, C68; Kidney 3 2.5 1.2 (0.2–3.6) 3 4.0 0.7 (0.1–2.2)
C67; Bladder 3 4.5 0.7 (0.1–2.0) 2 6.4 0.3 (0.0–1.2)
C70–C72; Brain and central nervous system 8 2.3 3.5 (1.5–7.0) 8 2.5 3.2 (1.4–6.3)
C73; Thyroid 0 2.2 — 0 3.6 —
C81; Hodgkin lymphoma 47 2.6 18.0 (13.2–23.9) 37 1.8 20.7 (14.6–28.5)
C90; Multiple myeloma/plasma cell neoplasm 3 0.5 5.5 (1.0–16.4) 4 1.0 3.9 (1.0–10.0)
C91–C95; Leukaemias, all 11 2.2 4.9 (2.4–8.8) 3 2.7 1.1 (0.2–3.3)
C26, C39, C48, C76, C80; Unk/ill-defined primary site 3 1.2 2.5 (0.5–7.4) 5 1.3 3.9 (1.2–9.2)
Total non-AIDS-defining cancers 162 68.3 2.4 (2.0–2.8) 221 100.7 2.2 (1.9–2.5)
py¼person-years, NHL¼non-Hodgkin lymphoma, Unk¼unknown.
aCancers reported to cancer registries in people with AIDS, aged 16–69 years, between 1986 and 2004
from 5 years prior to 10 years after AIDS diagnosis (at/after AIDS for AIDS-defining cancers).
bWomen only.
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A total of 21951 AIDS cases (78% men and 22% women) were
reported in Italy between 1986 and 2005 in areas covered by a CR
(Table 1). The number of person-years available (56643 and
45026, respectively), as well as number of cancers reported (1098
and 897), was similar in 1986–1996 and 1997–2004 (Table 2).
However, the proportion of IDUs (63 and 42%, respectively) and
the median age (32 and 38 years) varied substantially in the two
periods, as did the relative importance of different cancer types.
Kaposi sarcoma and NHL represented 84.4% of all cancers in
1986–1996, but 72.0% in 1997–2004. Marked declines in SIR
emerged for KS (from 1792 to 572, respectively) and NHL (from
497 to 93), whereas the SIR for the combination of non-AIDS-
defining cancers did not change (2.4; 95% CI: 2.0–2.8 and 2.2; 95%
CI: 1.9–2.5).
A significantly elevated risk emerged in 1997–2004 for cancer of
the liver (6.4; 95% CI: 3.7–10.5) and penis (12.0; 95% CI: 2.3–
35.5), whereas the excess risk for leukaemia disappeared. Elevated
SIRs for cancer of the anus (44.0; 95% CI: 21.8–78.9), vulva and
vagina (24.3; 95% CI: 4.6–71.8), lung (4.1; 95% CI: 2.9–5.5), brain
(3.2; 95% CI: 1.4–6.3), skin (non-melanoma, 1.8; 95% CI:1.2–2.6),
HL (20.7; 95% CI: 14.6–28.5), and multiple myeloma (3.9; 95% CI:
1.0–10.0) in 1997–2004 were similar to those found in 1986–1996
(Table 2). The comparison between the two periods was not
modified by the exclusion of CRs that contributed information for
the most recent period only (data not shown).
Persons with HIV/AIDS born outside Italy contributed 15% of
person-years and 7.8% of cancer cases in 1997–2004. They showed
similar SIR for AIDS-defining illnesses and slightly lower SIR of
non-AIDS-defining cancers (1.5; 95% CI: 0.7–2.4) than PWHA
born in Italy (data not shown).
Microscopic confirmation was available after 1996 for all ICC,
anal cancer, and HL (16 mixed cellularity, 7 nodular sclerosis, and
14 HL of unspecified type), as well as 79% of lung cancer. Eleven
out of 16 liver cancers were microscopically or instrumentally
confirmed. Microscopic confirmation was available for only one (a
glioma) out of eight brain tumours, and seven had a concomitant
AIDS-defining illness in the brain (six toxoplasmosis and one
leukoencephalopathy).
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Figure 1 Standardised incidence ratio (SIR) and corresponding 95% confidence interval of selected cancers in persons with HIV/AIDS by time of cancer
occurrence with respect to AIDS diagnosis. Italy, 1997–2004
a. Abbreviations: KS: Kaposi sarcoma, NHL: non-Hodgkin lymphoma, NADC: non-AIDS-
defining cancers, HL: Hodgkin lymphoma.
aCancers reported to cancer registries in people with AIDS, aged 16–69 years, from 5 years prior to 10 years after
AIDS diagnosis (at/after AIDS for AIDS-defining cancers).
bVertical bars represent 95% confidence intervals.
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emerged in the 3 months prior to or after AIDS diagnosis
(Figure 1). Prior to AIDS diagnosis, a significant risk excess was
only seen for HL (SIR¼11.2; 95% CI: 4.5–23.3), whereas elevated
SIRs emerged for all examined cancers 4–120 months after AIDS
diagnosis.
SIR years for KS, NHL, and HL were lower among PWHA
younger than 35 compared with older ones, whereas those for non-
AIDS-defining cancers other than HL were higher (Table 3).
Women showed higher SIR of KS, NHL, and cancer of the liver and
lung than men, whereas the opposite was found for HL. With
respect to HIV transmission category, SIRs were especially high for
cancer of the liver and lung among IDUs, and for KS and HL
among MSM. For all non-AIDS-defining cancers, the SIR was 3.6
(95% CI: 2.9–4.3) among IDUs, 1.4 (95% CI: 1.1–1.8) among
heterosexuals, and 2.0 (95% CI: 1.5–2.6) among MSM (Table 3).
Persons with HIV/AIDS who had less than 1-year interval
between first HIV-positive test and AIDS diagnosis differed from
other PWHA in many ways (Table 4). Among these late presenters,
the contribution of person-years was much larger among
heterosexuals, MSM, and PWHA born outside Italy, whereas
HAART use was rarer and median CD4þ cell count at AIDS
diagnosis was lower than in other PWHA. The SIR for KS (1252)
was also higher in late presenters than in other PWHA (Table 4).
Conversely, SIR for non-AIDS-defining cancers increased from 1.3
(95% CI: 1.0–1.7) in PWHA whose interval between first HIV-
positive test and AIDS diagnosis was less than 1 year, to 2.8 (95%
CI: 2.2–3.5) and 3.9 (95% CI: 2.9–5.0), respectively, in PWHA in
whom the corresponding interval was 1–9 years and 10 years or
more (Table 4).
DISCUSSION
Our study showed substantial changes in the cancer pattern
of Italian PWHA after the introduction of HAART in 1996.
Non-Hodgkin lymphoma replaced KS as the most frequent cancer
type and non-AIDS-defining cancers increased from 15 to 25% of
all cancers. For the first time a significant excess of liver cancer
emerged in the Italian AIDS linkage study (Dal Maso et al, 2003),
in agreement with record-linkage studies from the United States
(Engels et al, 2006; Patel et al, 2008) and findings from HIV
cohorts in Italy (Serraino et al, 2007) and Switzerland (Clifford
et al, 2005). As PWHA live longer, the appearance of an excess of
liver cancer compared with the general population was predictable
owing to the high prevalence of hepatitis B and, more notably,
hepatitis C infection among PWHA. An association between liver
cancer risk and low CD4þ cell count in the year preceding liver
cancer has recently been reported (Clifford et al, 2008), suggesting
that immunodeficiency may contribute to the liver cancer excess in
PWHA (Weber et al, 2006).
The risk of HL, myeloma, and cancers of the cervix, anogenital
tract, lung, brain, and skin (non-melanoma) continued to be
significantly increased among PWHA after 1996. The greatest
cancer excess was found in proximity to AIDS diagnosis, but
persisted in the 10 years afterwards. Notably, elevated SIRs were
seen overall and in each HIV transmission category for cancers of
the cervix and the anogenital tract that are, in the vast majority,
associated with HPV infection (IARC, 2007). Hence, it is not yet
clear whether the partial immune reconstitution induced by
HAART will ultimately also have a favourable effect on HPV-
associated cancers (Frisch et al, 2000; Dorrucci et al, 2001; Ahdieh-
Grant et al, 2004; Heard et al, 2004). Inadequate coverage by
cervical cancer-screening programmes of women living with HIV,
despite ubiquitous access to HAART and regular contact with
medical services, has been suggested as the main reason for the
greater excess risk of ICC in countries such as Italy (Franceschi
et al, 2006) and Spain (Galceran et al, 2007) compared with the
United States and Northern Europe (Franceschi and Jaffe, 2007).
According to a survey of HIV clinics in Italy (Murri et al, 2006),
HIV care providers in Italy are well aware of screening needs, but
they fail to achieve good coverage among HIV-positive women
mainly for organisational reasons.
With respect to HL, our findings confirm previous reports
(Dal Maso et al, 2003; Biggar et al, 2006; Engels et al, 2006;
Patel et al, 2008), but, contrary to what has been suggested in the
United States (Biggar et al, 2006), the SIR for HL did not increase
compared with the pre-HAART period. It is noteworthy that
MSM showed particularly elevated SIRs for HL though not for
NHL in our study. The disappearance of excess risk for leukaemias
in recent years suggests an improvement in the distinction
between NHL and other lymphoid neoplasms (Dal Maso and
Franceschi, 2003), but an elevated SIR for myeloma was confirmed
in 1997–2004.
Table 3 Observed (Obs) cancers in persons with HIV/AIDS
a, standardised incidence ratio (SIR), and corresponding 95% confidence interval (CI) by age
group and HIV transmission category. Italy, 1997–2004
Gender Age group HIV transmission category
Men
(N¼17173)
(33964py)
Women
(N¼4891)
(11062py)
16–34
(18815py)
35–69
(26211py)
IDU
(21715py)
Heterosexual
(15021py)
MSM
(8290py)
ICD10; Cancer
type or site Obs
SIR
(95% CI) Obs
SIR
(95% CI) Obs
SIR
(95% CI) Obs
SIR
(95% CI) Obs
SIR
(95% CI) Obs
SIR
(95% CI) Obs
SIR
(95% CI)
AIDS-defining cancers
C46; Kaposi sarcoma 271 550 (487–620) 23 1066 (675–1601) 88 386 (309–475) 206 720 (625–826) 59 204 (155–263) 91 777 (625–954) 1441338 (1128–1575)
C82–C88, C96; NHL 275 85.6 (75.8–96.4) 77 138 (109–173) 10078.9 (64.2–96.0)252 101 (88.7–114) 15287.3 (73.9–102) 126 106 (88.3–126) 74 88.2 (69.3–111)
C53; Cervix uteri — — 30 41.5 (28.0–59.3) 1542.3 (23.6–69.9) 1540.7 (22.7–67.3) 1744.2 (25.7–70.9) 13 38.4 (20.4–65.9) — —
Non-AIDS-defining cancers
C21; Anus 8 43.3 (18.5–85.7) 3 45.8 (8.6–136) 496.6 (25.1–250) 733.5 (13.3–69.4) 785.1 (33.7–176) 1 9.6 (0.0–55.1) 3 47.0 (8.9–139)
C22; Liver 14 5.9 (3.2–9.8) 2 20.3 (1.9–74.8) 424.3 (6.3–62.9) 12 5.2 (2.7–9.0) 1122.2 (11.0–39.9) 2 1.8 (0.2–6.5) 3 3.5 (0.7–10.3)
C33–C34; Lung 38 3.9 (2.8–5.4) 4 6.4 (1.7–16.5) 818.3 (7.8–36.2) 34 3.5 (2.4–4.8) 1911.0 (6.6–17.3) 11 2.2 (1.1–4.0) 12 3.3 (1.7–5.8)
C44; Skin non-melanoma 21 1.6 (1.0–2.5) 7 2.4 (1.0–5.0) 6 2.4 (0.9–5.2) 22 1.7 (1.0–2.5) 14 2.9 (1.6–4.9) 8 1.2 (0.5–2.3) 6 1.5 (0.5–3.2)
C81; Hodgkin lymphoma 35 25.9 (18.0–36.0) 2 4.6 (0.4–16.9) 1113.2 (6.6–23.8) 2627.2 (17.7–39.8) 1618.4 (10.5–29.9) 8 13.8 (5.9–27.3) 13 38.6 (20.4–66.1)
Total non-AIDS-defining
cancers
182 2.3 (2.0–2.7) 39 1.7 (1.2–2.4) 55 3.4 (2.6–4.4) 166 2.0 (1.7–2.3) 106 3.6 (2.9–4.3) 64 1.4 (1.1–1.8) 51 2.0 (1.5–2.6)
py¼person-years, IDU¼injecting drug users, MSM¼men who have sex with men, NHL¼non-Hodgkin lymphoma.
aCancers reported to cancer registries in people with
AIDS, aged 16–69 years from 5 years prior to 10 years after AIDS diagnosis (at/after AIDS for AIDS-defining cancers).
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confirmed (Grulich et al, 2007), but it is likely to derive mainly
from the high proportion of smokers, notably among IDUs
(Clifford et al, 2005). Conversely, we found no excess for head and
neck cancers, which are also associated with smoking and, in a
fraction of cases, HPV infection (Clifford et al, 2005; Kreimer et al,
2005). In respect to brain cancer, microscopic confirmation
continues to be very rare and misclassification with other HIV-
related diseases located in the brain cannot be ruled out.
Skin cancer (non-melanoma) was increased by two-fold in
PWHA as in previous reports (Franceschi et al, 1998; Allardice
et al, 2003; Dal Maso et al, 2003; Clifford et al, 2005). The excess
risk observed in PWHA was confirmed, however, to be weaker
than among transplant recipients (Grulich et al, 2007; Serraino
et al, 2007).
Standardised incidence ratios for a broad range of cancer sites,
including common neoplasms such as stomach, colon, breast, and
prostate, were close to unity and hence compatible with no
influence of immune status on the risk of several types of cancer.
Our present study has strengths and weaknesses. Strengths
include the large number of AIDS cases and person-years available
before and after HAART introduction. The completeness and
quality of the AIDS Registry (Conti et al, 1997) and Italian CRs
(Curado et al, 2007) have been shown to be satisfactory, and the
linkage procedures are accurate (Dal Maso et al, 2001; Clifford
et al, 2005). The limited population mobility, the strict rules for
maintenance of ‘legal residence’ in Italy, and the possibility of
verifing the vital status of PWHA with national mortality records
provided reassurance on the accuracy of follow-up and allowed us
to extend our observation period to 10 years after AIDS diagnosis.
Censoring at 5 years after AIDS diagnosis would not, however,
have modified our findings. Finally, microscopic or instrumental
confirmation was available for most cancer sites for which we
report risk increases. In particular, we were confident that no in
situ carcinomas were misclassified as ICC or anal cancer.
Systematic reporting of HIV cases in Italy is limited to a few areas
(Centro Operativo AIDS, 2008), and therefore a major weakness of
our present study is reliance on AIDS case reporting only. The
yearly number of AIDS cases has diminished three-fold in Italy
between the peak in the mid-1990s and 2000 (Centro Operativo
AIDS, 2008) and, most important, the meaning of AIDS onset has
changed. Formerly an irreversible stage of HIV progression, AIDS
often indicates, in the post-HAART era, poor adherence to
treatment or development of resistance (Kaldor et al,2 0 0 9 ) .
The availability (as from 1996) of information on the date of first
HIV-positive test in the AIDS Registry allowed us, however, to focus
on PWHA who had concomitant, or nearly concomitant, HIV
infection and AIDS-defining illness. Such late presenters increased
in Italy from 20.5% in 1996 to 55.5% of AIDS cases in 2007 (Centro
Operativo AIDS, 2008). They were in the vast majority individuals
who had acquired HIV through sexual intercourse and, unlike IDUs
in the early phase of the HIV epidemic, did not perceive themselves
as at high risk for the infection (Borghi et al, 2008). Persons with
HIV/AIDS born outside Italy were also frequent. In addition, late
presenters had never taken HAART and were severely immuno-
compromised more often than AIDS cases who had been HIV-
positive for many years prior. With respect to cancer pattern, KS
greatly predominated over all other tumours.
Our study showed that to prevent cancer in PWHA with
increasing life expectancy, the use of HAART must be accom-
panied by more effective cancer-prevention strategies (Massad
et al, 2004), notably antismoking, cervical cancer screening
programmes, and, possibly, hepatitis C virus treatment. Improve-
ments in the timely identification of HIV-positive individuals is
also a priority in Italy to avoid the immunological deterioration
associated with delayed HAART use, and also to provide a better
tool to monitor the HIV epidemic (Borghi et al, 2008).
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Table 4 Distribution of selected characteristics at AIDS diagnosis, observed (Obs) cancers
a, standardised incidence ratio (SIR), and corresponding 95%
confidence interval (CI) by time elapsed since first HIV-positive test and AIDS. Italy, 1997–2004
Time between first HIV-positive test and AIDS diagnosis (years)
b
Characteristics o1 (14868py) 1–9 (13994py) X10 (9028py)
HIV transmission category
IDU 13% 53% 84%
Heterosexual 59% 30% 10%
MSM 28% 17% 6%
PWHA born outside Italy 25% 12% 4%
Median age (years) at AIDS diagnosis (IQR) 39 (33–49) 36 (32–41) 38 (35–41)
Median CD4 (cells/ml) at AIDS diagnosis (IQR) 47 (17–110) 80 (26–193) 102 (38–215)
PWHA using HAART at AIDS diagnosis 7% 61% 66%
ICD10; Cancer type or site Obs SIR (95% CI) Obs SIR (95% CI) Obs SIR (95% CI)
C46; Kaposi sarcoma 162 1252 (1067–1461) 77 444 (350–555) 35 414 (288–576)
C82–C85, C88, C96; NHL 114 100 (82.5–120) 110 91.9 (75.6–111) 104 187 (153–227)
C53; Cervix uteri 4 27.7 (7.2–71.7) 9 32.1 (14.5–61.1) 14 111 (60.7–187)
Total non-AIDS-defining cancers 58 1.3 (1.0–1.7) 74 2.8 (2.2–3.5) 57 3.9 (2.9–5.0)
py¼person-years, IDU¼injecting drug users, MSM¼men who have sex with men, IQR¼interquartile range (25–75 percentile), NHL¼non-Hodgkin lymphoma.
aCancers
reported to cancer registries in people with AIDS, aged 16–69 years from 5 years prior to 10 years after AIDS diagnosis (at/after AIDS for AIDS-defining cancers).
bTwelve (7%)
cancers and 19% of py were excluded, as date of first HIV-positive test was missing.
Cancer in people with AIDS in Italy in HAART era
L Dal Maso et al
845
British Journal of Cancer (2009) 100(5), 840–847 & 2009 Cancer Research UK
E
p
i
d
e
m
i
o
l
o
g
yREFERENCES
Ahdieh-Grant L, Li R, Levine AM, Massad LS, Strickler HD, Minkoff H,
Moxley M, Palefsky J, Sacks H, Burk RD, Gange SJ (2004) Highly active
antiretroviral therapy and cervical squamous intraepithelial lesions in
human immunodeficiency virus-positive women. J Natl Cancer Inst 96:
1070–1076
AIRT Working Group (2006) Italian cancer figures—report 2006: 1.
Incidence, mortality and estimates. Epidemiol Prev 30: 8–28
Allardice GM, Hole DJ, Brewster DH, Boyd J, Goldberg DJ (2003) Incidence
of malignant neoplasms among HIV-infected persons in Scotland. Br J
Cancer 89: 505–507
Ancelle-Park R (1993) Expanded European AIDS case definition. Lancet
341: 441
Biggar RJ, Jaffe ES, Goedert JJ, Chaturvedi A, Pfeiffer R, Engels EA (2006)
Hodgkin lymphoma and immunodeficiency in persons with HIV/AIDS.
Blood 108: 3786–3791
Borghi V, Girardi E, Bellelli S, Angeletti C, Mussini C, Porter K, Esposito R
(2008) Late presenters in an HIV surveillance system in Italy during the
period 1992–2006. J Acquir Immune Defic Syndr 49: 282–286
Breslow NE, Day NE (1987) Statistical Methods in Cancer Research, Vol. II,
The design and analysis of cohort studies. IARC Scientific publications
No 82 International Agency for Research on Cancer: Lyon
Centro Operativo AIDS (2008) Aggiornamento dei casi di AIDS notificati in
Italia e delle nuove diagnosi di infezione da HIV. Dicembre 2007.
Notizario dell’Istituto Superiore di Sanita ` 21(suppl 1): 3–23
Clifford GM, Polesel J, Rickenbach M, Dal Maso L, Keiser O, Kofler A,
Rapiti E, Levi F, Jundt G, Fisch T, Bordoni A, De Weck D, Franceschi S
(2005) Cancer risk in the Swiss HIV Cohort Study: associations with
immunodeficiency, smoking, and highly active antiretroviral therapy.
J Natl Cancer Inst 97: 425–432
Clifford GM, Rickenbach M, Polesel J, Dal Maso L, Steffen I, Ledergerber B,
Rauch A, Probst-Hensch NM, Bouchardy C, Levi F, Franceschi S (2008)
Influence of HIV-related immunodeficiency on the risk of hepatocellular
carcinoma. AIDS 22: 2135–2141
Conti S, Farchi G, Galletti A, Masocco M, Napoli PA, Pezzotti P, Rezza G,
Toccaceli V, Cariani G (1997) La notifica della mortalita ` per AIDS in
Italia (1992): qualita ` della certificazione e sottonotificata. Giornale
Italiano dell’AIDS 8: 12–16
Curado MP, Edwards B, Shin HR, Storm H, Ferlay J, Heanue M, Boyle P
(eds) (2007) Cancer Incidence in Five Continents, Vol. IX International
Agency for Research on Cancer: Lyon
Dal Maso L, Franceschi S (2003) Epidemiology of non-Hodgkin lymphomas
and other haemolymphopoietic neoplasms in people with AIDS. Lancet
Oncol 4: 110–119
Dal Maso L, Franceschi S, Polesel J, Braga C, Piselli P, Crocetti E, Falcini F,
Guzzinati S, Zanetti R, Vercelli M, Rezza G, for the Cancer and AIDS
Registry Linkage Study (2003) Risk of cancer in persons with AIDS in
Italy, 1985–1998. Br J Cancer 89: 94–100
Dal Maso L, Tirelli U, Polesel J, Franceschi S (2005) Trends in cancer
incidence rates among HIV-infected patients. Clin Infect Dis 41: 124–126
Dal Maso L, Braga C, Franceschi S (2001) Methodology used for ‘software
for automated linkage in Italy’ (SALI). J Biomed Inform 34: 387–395
Dorrucci M, Suligoi B, Serraino D, Tirelli U, Rezza G (2001) Incidence of
invasive cervical cancer in a cohort of HIV-seropositive women before
and after the introduction of highly active antiretroviral therapy. J Acquir
Immune Defic Syndr 26: 377–380
Engels EA, Biggar RJ, Hall HI, Cross H, Crutchfield A, Finch JL, Grigg R,
Hylton T, Pawlish KS, McNeel TS, Goedert JJ (2008) Cancer risk in
people infected with human immunodeficiency virus in the United
States. Int J Cancer 123: 187–194
Engels EA, Pfeiffer RM, Goedert JJ, Virgo P, McNeel TS, Scoppa SM, Biggar
RJ (2006) Trends in cancer risk among people with AIDS in the United
States 1980–2002. AIDS 20: 1645–1654
Franceschi S, Dal Maso L, Arniani S, Crosignani P, Vercelli M, Simonato L,
Falcini F, Zanetti R, Barchielli A, Serraino D, Rezza G, for the Cancer and
AIDS Registry Linkage Study (1998) Risk of cancer other than Kaposi’s
sarcoma and non-Hodgkin’s lymphoma in persons with AIDS in Italy.
Cancer and AIDS Registry Linkage Study. Br J Cancer 78: 966–970
Franceschi S, Dal Maso L, Pezzotti P, Polesel J, Braga C, Piselli P, Serraino D,
Tagliabue G, Federico M, Ferretti S, De Lisi V, La Rosa F, Conti E, Budroni
M, Vicario G, Piffer S, Pannelli F, Giacomin A, Bellu ´ F, Tumino R, Fusco M,
Rezza G, for the Cancer and AIDS Registry Linkage Study (2003) Incidence
of AIDS-defining cancers after AIDS diagnosis among people with AIDS in
Italy, 1986–1998. J Acquir Immune Defic Syndr 34: 84–90
Franceschi S, Dal Maso L, Rickenbach M, Polesel J, Hirschel B, Cavassini M,
Bordoni A, Elzi L, Ess S, Jundt G, Mueller N, Clifford GM, the Swiss HIV
Cohort Study (2008) Kaposi sarcoma incidence in the Swiss HIV Cohort
Study before and after highly active antiretroviral therapy. Br J Cancer
99: 800–804
Franceschi S, Dal Maso L, Suligoi B, Rezza G (2006) Evidence for lack of
cervical cancer screening among HIV-positive women in Italy. Eur J
Cancer Prev 15: 554–556
Franceschi S, Jaffe H (2007) Cervical cancer screening of women living with
HIV: a must in the post-ART era. Clin Infect Dis 45: 510–513
Frisch M, Biggar RJ, Goedert JJ (2000) Human papillomavirus-associated
cancers in patients with human immunodeficiency virus infection and
acquired immunodeficiency syndrome. J Natl Cancer Inst 92: 1500–1510
Galceran J, Marcos-Gragera R, Soler M, Romaguera A, Ameijide A,
Izquierdo A, Borras J, de Sanjose SL, Casabona J (2007) Cancer incidence
in AIDS patients in Catalonia, Spain. Eur J Cancer 43: 1085–1091
Grulich AE, Li Y, McDonald A, Correll PK, Law MG, Kaldor JM (2002)
Rates of non-AIDS-defining cancers in people with HIV infection before
and after AIDS diagnosis. AIDS 16: 1155–1161
Grulich AE, Tvan Leeuwen M, Falster MO, Vajdic CM (2007) Incidence of
cancers in people with HIV/AIDS compared with immunosupressed
transplant recipients: a meta-analysis. Lancet 370: 59–67
Heard I, Palefsky JM, Kazatchkine MD (2004) The impact of HIV antiviral
therapy on human papillomavirus (HPV) infections and HPV-related
diseases. Antivir Ther 9: 13–22
Herida M, Mary-Krause M, Kaphan R, Cadranel J, Poizot-Martin I,
Rabaud C, Plaisance N, Tissot-Dupont H, Boue F, Lang JM,
Costagliola D (2003) Incidence of non-AIDS-defining cancers before
and during the highly active antiretroviral therapy era in a cohort
of human immunodeficiency virus-infected patients. J Clin Oncol 21:
3447–3453
Hessol NA, Pipkin S, Schwarcz S, Cress RD, Bacchetti P, Scheer S (2007) The
Impact of Highly Active Antiretroviral Therapy on Non-AIDS-Defining
Cancers among Adults with AIDS. Am J Epidemiol 165(10): 1143–1153
IARC (2007) Monographs on the Evaluation of carcinogenic risks to
Humans Volume 90: Human Papillomaviruses. IARC Press: Lyon
Kaldor JM, Delpech V, Guy RJ (2009) AIDS case reporting: do we still need
it? Lancet 373(9658): 181–183
Kreimer AR, Clifford GM, Boyle P, Franceschi S (2005) Human papilloma-
virus types in head and neck squamous cell carcinomas worldwide: a
systematic review. Cancer Epidemiol Biomarkers Prev 14: 467–475
Massad LS, Seaberg EC, Watts DH, Hessol NA, Melnick S, Bitterman P,
Anastos K, Silver S, Levine AM, Minkoff H (2004) Low incidence of
invasive cervical cancer among HIV-infected US women in a prevention
program. AIDS 18: 109–113
Murri R, Franceschi S, Ravizza M, Fiore S, Bini T, Mussini C, Fasolo M,
Liuzzi G, Ippolito G, D’Arminio MA (2006) Access to gynecological
services and Papanicolau tests in HIV-infected Italian women: a
questionnaire survey. AIDS Care 18: 376–378
Parkin DM, Muir C, Whelan S, Gao YT, Ferley J, Powell J (1992) Cancer
Incidence in Five Continents Vol. VI, IARC Scientific Publications No.
120 International Agency for Research on Cancer: Lyon
Parkin DM, Whelan SL, Ferlay J, Raymond L, Young J (1997) Cancer
Incidence in Five Continents Vol. VII, IARC Scientific Publications No.
143 International Agency for Research on Cancer: Lyon
Parkin DM, Whelan SL, Ferlay J, Thomas DB, Teppo L (2002) Cancer
Incidence in Five Continents, Vol. VIII. IARC scientific publications, no.
155 International Agency for Research on Cancer, 2002: Lyon, France
Patel P, Hanson DL, Sullivan PS, Novak RM, Moorman AC, Tong TC,
Holmberg SD, Brooks JT (2008) Incidence of types of cancer among HIV-
infected persons compared with the general population in the United
States, 1992–2003. Ann Intern Med 148: 728–736
Polesel J, Clifford GM, Rickenbach M, Dal Maso L, Battegay M, Bouchardy
C, Furrer H, Hasse B, Levi F, Probst-Hensch NM, Schmid P, Franceschi S,
the Swiss HIV Cohort Study (2008) Non-Hodgkin lymphoma incidence
in the Swiss HIV Cohort Study before and after highly active
antiretroviral therapy. AIDS 22: 301–306
Serraino D, Piselli P, Busnach G, Burra P, Citterio F, Arbustini E,
Baccarani U, De JE, Pozzetto U, Bellelli S, Polesel J, Pradier C, Dal Maso
L, Angeletti C, Carrieri MP, Rezza G, Franceschi S (2007) Risk of cancer
following immunosuppression in organ transplant recipients and in
HIV-positive individuals in southern Europe. Eur J Cancer 43:
2117–2123
Cancer in people with AIDS in Italy in HAART era
L Dal Maso et al
846
British Journal of Cancer (2009) 100(5), 840–847 & 2009 Cancer Research UK
E
p
i
d
e
m
i
o
l
o
g
yWeber R, Sabin CA, Friis-Moller N, Reiss P, El-Sadr WM, Kirk O
, Dabis F, Law MG, Pradier C, De WS, Akerlund B, Calvo G,
Monforte A, Rickenbach M, Ledergerber B, Phillips AN, Lundgren JD
(2006) Liver-related deaths in persons infected with the human
immunodeficiency virus: the D:A:D study. Arch Intern Med 166:
1632–1641
World Health Organisation (1992) International Classification of Diseases,
10th revision. WHO: Geneva
Appendix
Members of the CARL study include: Antonella Zucchetto, Angela
De Paoli (Epidemiology and Biostatistics Unit, Aviano); Americo
Colamartini (Romagna Cancer Registry, Meldola); Mariangela
Autelitano (Cancer Registry of Milan); Emanuele Crocetti (Tuscany
Cancer Registry); Enza Marani (Genoa Province Cancer Registry,
Genova); Anna Rita Fiore (Registro Tumori del Veneto, Padova);
Andrea Tittarelli (Registro Tumori Lombardia – Provincia di
Varese); Stefano Rosso (Piedmont Cancer Registry, City of Torino);
Ivan Rashid (Modena Cancer registry); Francesco Donato (Brescia
Health Unit Cancer Registry); Annamaria Pezzarossi (Reggio Emilia
Cancer Registry); Paolo Sgargi (Parma Province Cancer Registry);
Francesco La Rosa (Umbria Cancer Registry); Silva Franchini
(Trento Cancer Registry); Loris Zanier (Friuli Venezia Giulia Cancer
Registry); Rosaria Cesaraccio (Cancer Registry of Sassari); Gennaro
Senatore (Salerno Cancer Registry); Pier Carlo Vercellino (Piedmont
Cancer Registry, Province of Biella); Fabio Vittadello (Alto Adige/
Su ¨dtirol Cancer Registry); Raffaele Palombino (Campania Cancer
Registry); Maria Lia Contrino (Syracuse Province Registry of
Pathology); Silvia Antonini (Macerata Cancer Registry); Sergio
Maspero (Sondrio Cancer Registry); Maria Guglielmina La Rosa
(Ragusa Cancer Registry); Stefano Boros, Maria Cristina Salfa
(National Institute of Health, Rome)
Cancer in people with AIDS in Italy in HAART era
L Dal Maso et al
847
British Journal of Cancer (2009) 100(5), 840–847 & 2009 Cancer Research UK
E
p
i
d
e
m
i
o
l
o
g
y